Sir,

Human immunodeficiency virus (HIV) patients continue to be at high risk of acquiring bacterial bloodstream infections (BSIs) despite antiretroviral treatment.\[[@ref1]\] Clinical utility of high-class antibiotics, especially the third-generation cephalosporins and carbapenems as treatment options, drives the emergence of multidrug-resistant (MDR) bacteria.\[[@ref2]\] Studying bacterial etiology of BSI in HIV patients and understanding their resistance rate to antibiotics would help in the proper antibiotic selection for treatment regimens and avoid further emergence of antibiotic resistance. Reports on BSI and its antimicrobial resistance profile in HIV patients from southern India remain scarce. Hence, this study aimed to retrospectively analyze (2009--2017) the bacterial etiology of BSI in HIV patients attending YRG CARE, Chennai, using conventional culture techniques, and from 2017, BSI was identified using BD BACTEC™ FX 40 automated blood culture system (Becton, Dickinson and Company, USA). Antibiotic-resistant profile was determined using Kirby--Bauer disc diffusion method as per the CLSI guidelines.\[[@ref3]\]

A total of 51 (5.24%) bacterial strains were isolated from blood specimens collected from 972 HIV patients. *Staphylococcus aureus* caused high level of BSI (47), followed by *Escherichia coli* (33.3%), *Klebsiella pneumoniae* (6%), *Salmonella* spp. (4%), *Pseudomonas aeruginosa* (2%), and *Enterococcus* spp. (2%). High positivity of BSI was observed in the year 2014 (*n* = 15; 29.4%) followed by 2016 (*n* = 10; 19.6%). Positivity of BSI was higher among male (74.5%; *n* = 38) than female (25.5%; *n* = 13) HIV patients. BSI was highly seen in patients within the age group of 31--45 years (mean age: 40.3 years). Hospitalized HIV patients showed higher rate of (*n* = 38; 74.5%) BSI. *S. aureus* strains from BSI were highly resistant to ofloxacin (75%), penicillin (71%), azithromycin (58.3%), erythromycin (54.2%), and methicillin/oxacillin (50%). *E. coli* exhibited high level of resistance to ampicillin (82.3%) followed by ceftazidime (82.3%), cefotaxime and ciprofloxacin (76.5%), and cefazolin, ceftriaxone, cefuroxime, levofloxacin, meropenem, and piperacillin (57.1%). A steep increase in resistance was observed among *E. coli* strains against amoxiclav (14.3%--57.1%), cefepime (14.3%--57.1%), and cefazolin, cefuroxime, and ceftriaxone (from 25% to 50%) from 2009 to 2017. *K. pneumoniae* isolates exhibited 100% resistance against ampicillin and ceftazidime, followed by 66.7% to cefotaxime, ciprofloxacin, and meropenem \[[Table 1](#T1){ref-type="table"}\].

###### 

Year-wise antibiotic resistance profile of *Staphylococcus aureus* and *Escherichia coli* isolated from bloodstream infections in human immunodeficiency virus patients

  Class of antibiotics                                                              Antibiotics      Study periods                                                    
  --------------------------------------------------------------------------------- ---------------- --------------- ------ ------ ------ ------ ------ ------ ------ ------
  *Staphylococcus aureus*                                                                                                                                             
   Fluoroquinolones                                                                 Ciprofloxacin    0               0      0      0      9.1    18.2   9.1    45.5   9.1
  Levofloxacin                                                                      0                0               0      0      0      0      16.7   66.7   16.7   
  Ofloxacin                                                                         11.1             5.5             0      0      5.5    22.2   16.6   27\.   5.5    
   Lincosamides                                                                     Clindamycin      0               0      0      0      16.7   33.3   16.7   16.7   16.7
   Tetracyclines                                                                    Doxycycline      0               0      0      0      33.3   0      0      33.3   0
   Macrolides                                                                       Azithromycin     0               0      0      0      7.1    21.4   28.6   28.6   7.1
  Erythromycin                                                                      0                0               0      0      7.7    31     23.1   23.1   7.7    
   Aminoglycosides                                                                  Gentamicin       0               11.1   0      0      11.1   33.3   11.1   22.2   0
   Antistaphylococcal β-lactams                                                     Oxacillin        25              8.3    0      0      0      8.3    16.6   25     8.3
   Penicillin                                                                       Penicillin       0               0      0      0      5.9    29.4   29.4   23.5   5.9
   Ansamycins                                                                       Rifampicin       33.3            0      0      0      0      11.1   11.1   33.3   11.1
  *Escherichia coli*                                                                                                                                                  
   Aminoglycosides                                                                  Amikacin         0               0      0      0      0      50     50     0      0
  Gentamicin                                                                        0                0               0      11.1   0      44.4   11.1   11.1   22.2   
   Penicillins + β-lactamase inhibitor                                              Amoxyclav        0               0      0      \-     0      \-     14.3   28.8   57.1
   Penicillins                                                                      Ampicillin       0               0      0      7.1    0      35.7   14.3   14.3   28.6
   Nonextended spectrum cephalosporins; 1^st^ and 2^nd^ generation cephalosporins   Cefazolin        0               0      0      \-     0      \-     25     25     50
  Cefuroxime                                                                        0                0               0      \-     0      \-     25     25     50     
   Extended-spectrum cephalosporins; 3^rd^ and 4^th^ generation cephalosporins      Cefepime         0               0      0      \-     0      \-     14.3   28.8   57.1
  Ceftazidime                                                                       0                0               0      7.1    0      35.7   14.3   14.3   28.6   
  Cephotoxime                                                                       0                0               0      7.7    0      38.5   15.4   15.4   23.1   
  Ceftriaxone                                                                       0                0               0      \-     0      \-     25     25     50     
   Cephamycins                                                                      Cefoxitin        0               0      0      \-     0      \-     40     40     20
   Fluoroquinolones                                                                 Ciprofloxacin    0               0      0      7.7    0      31     15.4   15.4   31
  Levofloxacin                                                                      0                0               0      0      0      \-     25     25     50     
   Folate pathway inhibitors                                                        Co-trimoxazole   0               0      0      14.3   0      \-     28.8   14.3   42.8
   Carbapenems                                                                      Imipenem         0               0      0      0      0      0      50     0      50
  Meropenem                                                                         0                0               0      0      0      12.5   25     25     37.5   
   Antipseudomonal penicillins + β-lactamase inhibitors                             Piperacillin     0               0      0      \-     0      \-     25     25     50
  Piperacillin-tazobactam                                                           0                0               0      \-     0      \-     66.6   0      33.3   
   Tetracyclines                                                                    Tetracycline     0               0      0      \-     0      \-     33.3   33.3   33.3

Immune dysregulation among HIV patients results in increased risk of morbidity due to *S. aureus* causing BSI.\[[@ref1]\] Gram-negative bacteria were reported to be responsible for one-fifth of all BSIs, among which *E. coli* and *P. aeruginosa* were reported more frequently.\[[@ref4]\] Contrarily, here, Gram-positive bacteria (*S. aureus*; 47%) caused high level of BSI than Gram-negative bacteria (*E. coli*; 33.3%). From Malawi,\[[@ref5]\] a 19-year surveillance study reported that *E. coli*, *S. aureus*, and *Klebsiella* spp. caused 8.8%, 6.6%, and 4.4% of BSI in non-HIV patients, respectively. In this current study, *E. coli* exhibited extended resistance profile to carbapenem antibiotics (39.6%), especially against imipenem (50%), which is contrasting to the other study where *E. coli* isolated from HIV patients had shown 100% sensitivity to imipenem.\[[@ref6]\] Increased level of antibiotic resistance makes difficult the treatment of BSI caused by carbapenem-resistant Enterobacteriaceae and also by aminoglycoside and fluoroquinolone resistant bacteria. This study concludes that methicillin-resistant *S. aureus* (MRSA) and the third-generation cephalosporin- and carbapenem-resistant *Enterobacteriaceae* were the main etiological agents responsible for BSI in HIV patients. Incidence of MRSA and MDR *Enterobacteriaceae* increases the severity of BSI due to its resistance profile, making clinical management and antibiotic selection highly challenging in our resource-limited HIV care setting.
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